CI’s 10th Pathways to Access Forum Mastering Market Access Sponsored by MORSE Consulting Inc.
The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.
Innovative Performance-based Agreement Structures for DRD’s
The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.
Accelerating Access: Leveraging Target Zero to Expedite Time to Access for New Therapies
On September 5th, 2024, Katherine Scott and Lana Duan from MORSE Consulting presented “Accelerating Access: Leveraging Target Zero to Expedite Time to Access for New Therapies” at the CDA-AMC Symposium. They explored how pre-NOC submissions impact market access timelines, using CDA-validated data and insights from our internal database.Download our presentation to learn more about these findings and strategies for accelerating access to new therapies.…
CRaFT Mid-Year Update is Here!
We’re excited to announce that the 2024 Canadian Reimbursement & Forecasting Timelines (CRaFT) Mid-Year Update is now available! If you’re subscribed, you can now access the latest insights and data to enhance your market access strategies here: MORSE Reports Portal Not a subscriber yet? Don’t miss out—subscribe now to stay informed and take advantage of this valuable resource! MORSE Subscriptions
Challenges with Integrating Early-Stage Cancer Trial Endpoints into Economic Models: Review of Canadian and International HTA Recommendations
The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.
The Evolution of the Canadian Drug Agency: A Market Access Connoisseur’s Guide [2024]
MORSE's Sang Mi Lee joins a podcast with Exactis Innovation discussing the intricacies of Canada's drug reimbursement system and how it might evolve with the recent creation of the Canadian Drug Agency (CDA). Summary: With national pharmacare closer to reality in Canada, our insightful conversation with market access professionals and seasoned pharmacists, Sang Mi Lee, MBA, BSc Phm, RPh and Brian O’Rourke, sheds light on the…
MORSE Consulting Releases its pCPA Quarterly Update – Q1 2024
MORSE Consulting Inc. is pleased to release our pCPA Quarterly Update infographic, which highlights key metrics from Q1 2024 compared to performance over the last year. For a more in-depth look at market access trends and timelines comparing 2023 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or…
Canadian Pathway to Rare Disease Drug Access: Snapshot on Where we Are With Time to Access
At MORSE Consulting, we're delighted to share insights from Sherry O'Quinn's recent participation at the Rare Disease Day 2024 Summit held by the Canadian Organization for Rare Disorders (CORD) in Ottawa. The conference, themed around sustaining the momentum of two decades of impactful work in the rare disease community, was insightful and inspiring. Sherry had the opportunity to present a snapshot on the…
The Way Ahead for Cell and Gene Therapies: How to Create Healthcare System Infrastructure that Supports New Pathways to Access and Reimbursement
The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.
MORSE Consulting Releases its pCPA Quarterly Update – Q4 2023
MORSE Consulting Inc. is pleased to release our pCPA Quarterly Update infographic highlighting key metrics from Q4 2023 compared to performance over the last year. For a more in-depth look at market access trends and timelines comparing 2022 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see…
Season’s Greetings from MORSE Consulting 2023
Happy Holidays from MORSE Consulting! As we enter the festive season and the close of our seventh year of operations, we wish to express our heartfelt gratitude to the Pharmaceutical Market Access community, including our clients, strategic partners, and team members In appreciation of your continued support, MORSE has made a donation to the Ottawa and Toronto Food Banks to help support families…
Challenges and Success with Win-Win-Win-Win Negotiations – Fall 2023 CORD Conference
The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.
MORSE Consulting Releases its pCPA Quarterly Update – Q3 2023
MORSE Consulting Inc. is pleased to release our pCPA Quarterly Update infographic highlighting key metrics from Q3 2023 compared to performance over the last year. For a more in-depth look at market access trends and timelines comparing 2022 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see…
Exciting Announcement: MORSE Consulting Welcomes Ben Faienza as Strategic Advisor
Toronto, ON – October 3, 2023 – MORSE Consulting is delighted to announce a formal collaboration with Ben Faienza, President and Principal of F5 Management Consulting, as a Strategic Advisor. This collaboration represents a significant milestone for our firm, enhancing our market access capabilities. F5 Management Consulting, established in February 2023, provides strategic and operational guidance to bio-pharmaceutical companies entering the Canadian market. With…
Unlocking the Future of Pharmaceutical Market Access: MORSE Consulting and Medlior Health Outcomes Research Join Forces
September 14, 2023 - We are thrilled to announce a groundbreaking collaboration between MORSE Consulting and Medlior Health Outcomes Research, two leaders in the Canadian pharmaceutical market access landscape. This partnership aims to blend MORSE Consulting's unparalleled expertise in payer and HTA strategies with Medlior's cutting-edge real-world evidence solutions, offering our clients an unmatched array of services to navigate the complex world of pharmaceutical…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
MORSE Signals | MORSE Consulting Inc.
